ANTI-SARS-COV-2 DRUG
The present invention provides a compound, a salt thereof, a solvate thereof, or a prodrug thereof; and an anti-SARS-CoV-2 drug containing the same. The compound is represented by formula (1) [where: R1, R2, and R3 are the same or different and each a hydrogen atom, a halogen atom, a substituted or unsubstituted C1-6-alkyl group, a substituted or unsubstituted C1-6-alkoxy group, or -N(Ra)(Rb) (where Ra and Rb are the same or different and each a substituted or unsubstituted C1-10-alkyl group or a substituted or unsubstituted aryl group, and Ra and Rb may form a substituted or unsubstituted 5- to 7-membered ring in conjunction with an adjacent nitrogen atom); R4 is -N(Ra)(Rb)(where Ra and Rb are the same or different and each a substituted or unsubstituted C1-10-alkyl group or a substituted or unsubstituted aryl group, and Ra and Rb may form a substituted or unsubstituted 5- to 7-membered ring in conjunction with an adjacent nitrogen atom); X is a hydrogen atom, a fluorine atom, a chlorine atom, a bromine atom, or an iodine atom; and the hydroxyl group in the formula may be substituted with a protecting group]..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Europäisches Patentamt - (2023) vom: 19. Mai Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
BABA MASANORI [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2023-05-19, Last update posted on www.tib.eu: 2024-03-07, Last updated: 2024-03-08 |
|---|
| Patentnummer: |
WO2023085392 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA017412293 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA017412293 | ||
| 003 | DE-627 | ||
| 005 | 20240308100724.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230630s2023 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA017412293 | ||
| 035 | |a (EPA)WO2023085392 | ||
| 035 | |a (EPA)86335828 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a BABA MASANORI |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a ANTI-SARS-COV-2 DRUG |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2023-05-19, Last update posted on www.tib.eu: 2024-03-07, Last updated: 2024-03-08 | ||
| 520 | |a The present invention provides a compound, a salt thereof, a solvate thereof, or a prodrug thereof; and an anti-SARS-CoV-2 drug containing the same. The compound is represented by formula (1) [where: R1, R2, and R3 are the same or different and each a hydrogen atom, a halogen atom, a substituted or unsubstituted C1-6-alkyl group, a substituted or unsubstituted C1-6-alkoxy group, or -N(Ra)(Rb) (where Ra and Rb are the same or different and each a substituted or unsubstituted C1-10-alkyl group or a substituted or unsubstituted aryl group, and Ra and Rb may form a substituted or unsubstituted 5- to 7-membered ring in conjunction with an adjacent nitrogen atom); R4 is -N(Ra)(Rb)(where Ra and Rb are the same or different and each a substituted or unsubstituted C1-10-alkyl group or a substituted or unsubstituted aryl group, and Ra and Rb may form a substituted or unsubstituted 5- to 7-membered ring in conjunction with an adjacent nitrogen atom); X is a hydrogen atom, a fluorine atom, a chlorine atom, a bromine atom, or an iodine atom; and the hydroxyl group in the formula may be substituted with a protecting group]. | ||
| 650 | 4 | |a C07D: Heterocyclic compounds (macromolecular compounds c08) | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a OKAMOTO MIKA |4 aut | |
| 700 | 0 | |a TOYAMA MASAAKI |4 aut | |
| 700 | 0 | |a AOKI SHIN |4 aut | |
| 700 | 0 | |a TANAKA TOMOHIRO |4 aut | |
| 700 | 0 | |a YOKOI KENTA |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2023) vom: 19. Mai |
| 773 | 1 | 8 | |g year:2023 |g day:19 |g month:05 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/86335828/publication/WO2023085392A1?q=WO2023085392 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 19 |c 05 | ||